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$58,000 per year of life saved and $124,000 per quality-
adjusted year of life saved. For the lifetime projection, it
was unlikely to have ratios $28,000 per year of life saved
and $54,000 per quality-adjusted year of life saved.
CONCLUSIONS: Among patients whose heart failure
was due to nonischemic dilated cardiomyopathy, amlo-
dipine therapy was good value for the cost. An economic
evaluation should be repeated when the second PRAISE
study—which was designed to evaluate the mortality ef-
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OBJECTIVES: An international review of cost-effective-
ness studies of pharmaceuticals published in the last 5
years in peer reviewed journals was undertaken to identify
the extent to which “state of the art” methodology and ana-
lytical techniques had been employed.
METHODS: Three main approaches were taken for this
review: (1) A literature search for cost-effectiveness analy-
ses of pharmaceuticals 1994–99 was undertaken using
MEDLINE and other databases; (2) A list of “state of the
art” methods and analytical techniques (defined as new
and innovative, rather than established) were drawn from
“methods” papers published in leading health economics
journals in the past 10 years, and peer opinion; (3) Appli-
cation of a simple quality scoring system to assess the
quality of the reviewed papers.
RESULTS: 30 (currently) economic evaluations of phar-
maceuticals have to date been identified, originating from
several countries. The “state of the art” methods list in-
cluded developments in a several main areas: data collec-
tion and modelling approaches (e.g., RCTs, meta analysis
and scenario analysis), cost measurement, analysis and
handling uncertainty (e.g., confidence intervals for ICERs,
Monte Carlo simulations, Bayesian approaches to sensitiv-
ity analysis). The quality scoring system is still in develop-
ment (although pilot results hopefully due soon). The main
finding was that only a few of the studies reviewed used
“state of the art” methods, relying mostly on established
approaches to CEA.
CONCLUSIONS: The development of new state of the art
methods in CEA in recent years, in particular with new de-
velopments in statistical applications, has increased poten-
tial quality and rigour of CEA results. However, these
methods are not yet routinely used in actual pharmaceco-
nomic evaluations and may not be until more fully inte-
grated into the growing number of pharmacoeconomic
guidelines (linked to drug reimbursement) being produced
in different countries.
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OBJECTIVES: There is growing interest in the economic
evaluation of pharmaceuticals at the multinational level.
The purpose of these evaluations is to inform healthcare
decision-makers about the cost-effectiveness of pharma-
ceuticals, whose interests are largely specific to their own
countries. The objective of this research is to identify and
critically appraise multinational economic evaluations re-
lating to pharmaceuticals in a number of disease areas, to
produce a comprehensive list of the methodological con-
siderations and to demonstrate how previous work can in-
form and ensure optimal design and analysis of future
multinational economic evaluations.
METHODS: A systematic review involving databases (in-
cluding MEDLINE, OHE, NHS) and hand-searches of
journals was conducted for multinational economic evalu-
ations. Each economic evaluation was assessed using a 70-
point checklist specifically developed for multinational
economic evaluations, which evaluated design issues (study
question, study bias, outcomes) and analysis issues (data
pooling, data presentation, data robustness and data gen-
eralisability) and also scored against a previously devel-
oped 35 point generic checklist based on the BMJ guide-
lines. Simultaneously a review was performed on the
literature on generalisability and a survey was conducted
in a number of countries to ascertain attitudes to general-
isability of data from multinational clinical trials.
RESULTS: 16 economic evaluations met the criteria for in-
clusion, which were based on a variety of frameworks and
all took the form of cost-effectiveness analyses (5  multi-
national clinical-economic trials, 7  adaptation of single
country clinical-economic trials and 4  multinational de-
cision-analytic models) With the 70-point checklist, it was
found that the studies addressed different subsections of
the checklist adequately and the quality of the studies
showed further variation using the 35-point checklist.
There were very few papers on generalisability, but the re-
sults of the survey demonstrated a degree of convergence.
CONCLUSIONS: Worldwide, the issue of multinational
economic evaluations is generating huge interest and is one
of the biggest challenges facing health economics today.
However this area has not been extensively researched and
there is an urgent need for additional methodological
work. This research is a first step towards developing a set
of guidelines for use in future studies relating to the design,
analysis and presentation of multinational economic
evaluations with the purpose of maximizing the general-
isability of these studies and hence their value to decision-
makers.
